Because the somewhat uniform distribution of hAAT appears to have provided a positive trend in as far as islet protection, using a lower dose per injection, we explored subcutaneous administration of hAAT as a clinically-favorable route that results in a relatively slow release of injected material.
← all excerpts
Exploration of α1-antitrypsin treatment protocol for islet transplantation: dosing plan and route of administration.
1
—
—